POLBF - Poolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drug
(NewsDirect)
Poolbeg Pharma PLC CEO Jeremy Skillingtonand Tim Coté CEO of Silk Road Therapeutics join Proactive'sStephen Gunnion with details of an exclusive 12-month option agreementwith Silk Road Therapeutics for Poolbeg to acquire a novel topicaldrug aimed at treating oral ulcers in patients with Behçet'sdisease, a rare and debilitating condition.
Skillington said the move is aligned withPoolbeg's strategic focus on rare and orphan diseases.
Coté, with an extensive background inorphan drug approvals from his time at the FDA, highlighted thepotential of the drug given its unique formulation and unmet need inthe market. He explained the severe impact of Behçet's disease,underscoring the innovative potential of their topical treatment inimproving the quality of life for those affected.
Both CEO expressed optimism about theircollaboration's potential to fast-track this novel treatment tomarket, leveraging Poolbeg’s and Silk Road's combinedexpertise.
Furthermore, Skillingtonprovided insights into Poolbeg’s financial health and strategicdevelopments over the past year, mentioning a robust cash position of£12.2 million at the end of 2023. He emphasised the company'sdisciplined capital allocation and the expansion of its intellectualproperty portfolio.
Looking ahead, Skillington outlinedPoolbeg's focus on progressing its pipeline, particularly ongoingprojects like POLB001 in the oncology sector, addressing cytokinerelease syndrome—a critical side effect in cancerimmunotherapies.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.